Please ensure Javascript is enabled for purposes of website accessibility

Gilead's Ebola Drug Shows Positive Signs in Treating Coronavirus

By Mark Prvulovic - Feb 3, 2020 at 5:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of the biotech giant surged in light of the news.

Gilead Sciences (GILD 1.08%) shot up as much as 13% on the news that its failed Ebola drug, remdesivir, showed promising initial signs of helping patients with the coronavirus. In an official statement before the weekend, the company announced it was working together with U.S. and Chinese health regulators to see whether remdesivir could improve patient symptoms.

The company stated that remdesivir saw some success in treating patients with SARS and MERS, two other viruses with similarities with the coronavirus when tested in animals. Remdesivir was also tested on one U.S. coronavirus patient prior to the weekend, who showed an impressive improvement in symptoms following a single dose.

Close up depiction of virus cells in the body.

Image source: Getty Images.

The New England Journal of Medicine reported that a U.S. patient received a dose of remdesivir from doctors on a compassionate use basis. Whereas the patient had been showing signs of pneumonia, fever, and required supplemental oxygen, after remdesivir was given, all symptoms disappeared except for a cough and mucus buildup in the nasal cavity (rhinorrhea).

Further details

While impressive, further clinical tests need to be performed before Gilead's remdesivir can be recommended for widespread coronavirus treatment. Other pharmaceutical giants are also hoping to develop a treatment, with Johnson & Johnson and GlaxoSmithKline working on their own vaccines. AbbVie stated it saw positive results by mixing two HIV medications with another drug called Tamiflu.

However, the biggest winners over the past few weeks have been small-cap specialty vaccine producers. Moderna and Inovio Pharmaceuticals have seen substantial swings in their stock prices as the coronavirus continues to spread. There are now 362 confirmed deaths from the outbreak so far.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$64.35 (1.08%) $0.69
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$181.40 (1.09%) $1.96
GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
GSK
$45.00 (0.56%) $0.25
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$149.11 (0.73%) $1.08
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.77 (-7.81%) $0.15
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$132.06 (-4.04%) $-5.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
334%
 
S&P 500 Returns
117%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.